<DOC>
	<DOCNO>NCT01716624</DOCNO>
	<brief_summary>The purpose study investigate use Botulinum Toxin A primary therapy child neurogenic bladder due spina bifida compare result standard oral oxybutynin therapy . This study hop demonstrate Botulinum Toxin A maintain improve bladder storage function without side effect associate oxybutynin use .</brief_summary>
	<brief_title>Botox Versus Oxybutynin First Line Treatment Poorly Compliant Pediatric Neurogenic Bladder</brief_title>
	<detailed_description />
	<mesh_term>Urinary Bladder , Neurogenic</mesh_term>
	<mesh_term>Oxybutynin</mesh_term>
	<mesh_term>Botulinum Toxins , Type A</mesh_term>
	<mesh_term>abobotulinumtoxinA</mesh_term>
	<mesh_term>onabotulinumtoxinA</mesh_term>
	<mesh_term>incobotulinumtoxinA</mesh_term>
	<mesh_term>Botulinum Toxins</mesh_term>
	<mesh_term>Mandelic Acids</mesh_term>
	<criteria>Diagnosis spina bifida neurogenic bladder Performing clean intermittent catheterization ( CIC ) Taking 0.30.4 mg/kg/day oxybutynin poorly compliant bladder Has previous bladder surgery Has urodynamic videourodynamic study do within last 6 month Upper motor neuron ( UMN ) type bladder demonstrate last urodynamic study Urodynamic study ( UDS ) show either detrusor leak point pressure &gt; 40cm H2O ; 30cm capacity &lt; 60 % total bladder capacity , 20 cm capacity &lt; 70 % bladder capacity Able willing complete CIC Diaries Quality Life Questionnaires Consent assent give participate trial History lung disease , recurrent aspiration severe neurological impairment may increase risk Botox toxicity anesthesia Positive urine culture Known allergy Botox</criteria>
	<gender>All</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>20 Years</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>Pediatric</keyword>
</DOC>